Growth Hormone Deficiency Market - Size, Share, Industry Trends, and Forecasts (2025-2032)

By Type:

Based on type, the market is categorized into diagnosis and treatment.

Trends in Type:

• Rising prevalence has led to increased demand for genetic testing in diagnosing GHD.
• The emergence of novel treatment modalities beyond recombinant human growth hormone (rhGH).

The treatment segment accounted for the largest market share in 2024 and is expected to grow at the fastest CAGR over the forecast period.

• Treatment dominates due to its direct impact on patient outcomes and the growing need for effective solutions. Once a diagnosis is made, the primary goal is to manage the condition and improve the quality of life, which makes treatment central to the growth hormone deficiency market growth.
• The most approved hormones for GHD treatment are recombinant human growth hormones (rhGH), which are manufactured through biotechnology to mimic the naturally occurring growth hormone. These include well-known brands such as Somatropin and Somatrem. Advancements in treatment options are driving the segment.
• For instance, according to a study published by the National Center for Biotechnology Information, in 2023, long-acting hormone therapies involve altering the hormone's molecular structure (weight, charge, binding). These modifications influence how the hormone interacts with target tissues, potentially reducing side effects and improving treatment efficacy. This has expanded the reach for more patients, positively driving the segment.
• This, combined with the rising awareness of GHD, contributes to treatment being the dominant and fastest-growing segment of the market.
• Overall, as per the market analysis, advancements in treatment options are driving the segment in the market.

By Indication:

The indication segment is categorized into pediatric growth hormone deficiency and adult growth hormone deficiency.

Trends in the Indication

• Investigating GHD treatment in children with short stature born small for gestational age (SGA).
• Growing focus on improving diagnostic and treatment criteria for GHD in adults.

The pediatric growth hormone deficiency segment accounted for the largest market share in 2024.

• The pediatric segment dominates the market primarily due to the critical role growth hormones play during childhood. The early onset of disease in childhood leads to visible symptoms such as impaired linear development, short stature, and delayed skeletal maturation.
• These symptoms are usually identified during routine pediatric checkups or through parental concern, leading to earlier diagnosis and a higher demand for treatment in this age group.
• Moreover, pediatric medications require specific formulations and dosages tailored to the physiological and developmental characteristics of children. This necessitates dedicated research and development efforts, driving the market for pediatric-specific drugs. The rising prevalence amongst children is the driving segment in the market.
• For instance, according to an article published by Endocrine Society, in children GHD is prevalent in 1:4,000 to 1:10,000 cases. This has led to increased diagnosis and treatment options, driving segment.
• Additionally, rising awareness among parents through healthcare providers, social media, and traditional media channels highlighting the importance of early diagnosis and treatment, and providing accessible information about the condition and treatment options further drives the segment.
• As per the market analysis, the increasing prevalence, critical role of growth hormones in childhood, early symptom identification, the need for specialized formulations, and increasing parental awareness is driving segmental growth in the growth hormone deficiency industry.

The adult segment is expected to grow at the fastest CAGR over the forecast period.

• The adult segment is emerging due to increased awareness and improved understanding of the condition’s long-term health implications. Adult GHD is associated with metabolic, cardiovascular, and psychological health issues.
• Treatment for GHD typically includes recombinant human growth hormone (rhGH) therapies.Treatment in adults offers several benefits, including increased muscle mass and strength, reduced body fat, improved bone density, enhanced energy levels, and improved mood.
• By counteracting the age-related decline in natural growth hormone production, treatment helps maintain overall health, improve quality of life, and potentially reduce the risk of age-related health issues such as osteoporosis and cardiovascular disease.
• Overall, the rising prevalence of conditions such as pituitary gland dysfunction and tumors will drive the segment for the upcoming years.

By End User:

The end-user segment is categorized into hospitals, clinics, and others. 

Trends in End-User:

• Emergence of telemedicine in hospitals for patient monitoring and consultations.
• The growing role of community health centers in providing access to GHD diagnosis and treatment.

The hospitals segment accounted for the largest market share of 54.08% in 2024.

• Hospitals dominate the market due to their advanced infrastructure, specialized medical expertise, and ability to handle complex cases. Diagnosis requires sophisticated tests such as stimulation tests, MRI scans, and biochemical assays, which are typically available in hospitals.
• These facilities house multidisciplinary teams, including endocrinologists, pediatricians, and radiologists, who work collaboratively to ensure accurate diagnosis and effective treatment plans for both pediatric and adult patients.
• Their dominance is further driven by the high influx of patients due to referral systems, insurance coverage, and the trust associated with hospital-based treatments.
• The rising healthcare industry in terms of increased investment, technological advancements, growing diseases, and government regulations has led to increases in the number of hospitals.
• For instance, according toCEIC, the number of hospitals in China increased by 3.85% from 2022 to 2023, rising from 36 million units to 38 million units. Consequently, this surge in hospitals has contributed to increased accessibility to various patient populations, positively driving the segment in the market.
• Overall, according to market analysis, advanced infrastructure, specialized expertise, strong referral networks, and the growing number of hospitals are driving the segment.

The clinics segment is expected to grow at the fastest CAGR over the forecast period.

• Clinics are emerging in the market due to their accessibility and focus on outpatient care. Clinics offer a more personalized and convenient environment for patients seeking routine management of GHD.
• As awareness of GHD increases, clinics are becoming the first point of contact for patients with mild symptoms or those seeking follow-up care after a hospital diagnosis.
• The availability of endocrinologists and other specialists in clinics ensures that patients access high-quality care without the need for hospital visits.
• Additionally, clinics are expanding their capabilities by incorporating diagnostic tools, such as blood tests and imaging services, enabling them to cater to both pediatric and adult patients.
• Their cost-effectiveness, especially in emerging economies, are key factor driving the segment.
• Advancements in medical imaging, increased availability of hormonal assays, and increasing genetic testing clinics for accurate diagnosis of diseases and treatment will drive the segment for the forecasted years.